Adult T cell leukemia/lymphoma (ATL)

Research output: Contribution to journalReview articlepeer-review


Adult T cell leukemia/lymphoma(ATL) is an aggressive, fatal malignancy associated with human T-lymphotropic virus type I(HTLV-I). The median survival time of acute- and lymphoma-type ATL is 6 and 10 months, respectively. According to recent reports, nearly half of the ATL patients who received allogeneic hematopoietic stem cell transplantation could survive without disease for over 3 years. However, the population of patients who are eligible for conventional transplantation is extremely limited. Therefore, a reduced-intensity allogeneic stem cell transplantation(RIST) is applied to ATL patients and a multi-center phase I clinical trial is now underway. In our institute, 5 patients, who received RIST, are all alive, with 1 case relapsed after 6 months. Thus, RIST is considered very promising.

Original languageEnglish
Pages (from-to)1592-1595
Number of pages4
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number9
Publication statusPublished - 2003 Sept
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Adult T cell leukemia/lymphoma (ATL)'. Together they form a unique fingerprint.

Cite this